Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
Sunshine Biopharma Inc., a Colorado corporation headquartered in Fort Lauderdale, Florida, filed this Current Report on Form 8-K on April 2, 2025. The report discloses the issuance of a press release on April 1, 2025, announcing financial results for the fiscal year ended December 31, 2024. The Company's common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols SBFM and SBFMW, respectively.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced in a press release attached as Exhibit 99.1, which is not included in the provided text.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The filing references the full fiscal year results but does not summarize specific year-over-year variances or operational shifts.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the actual numerical financial results for the fiscal year ended December 31, 2024.
- Verify the Company's cash position and runway, as these are critical for biopharma entities and are not listed in this summary.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the full press release.
- Confirm the status of the Common Stock Purchase Warrants (SBFMW) and any potential dilution impacts.